Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You don't think that calling someone "toxic" and "egotistical" is an attack?
Why do you pumpers waste so much time insulting me? Why don't you talk about this stock or this company? Why am I such a perceived threat? Just ignore me. I know you won't ever present a counterpoint or try to discuss any topic, so why not just ignore me?
All Whelan has to do to silence naysayers is her job.
There's nothing so critically wrong with BIEL that it can't be fixed. This company isn't screwing shareholders the way ENDV is screwing shareholders, for example.
BIEL shareholders should thank me for trying to light a fire under CEO Whelan. She needs prodding and she definitely needs guidance.
But instead, the ignorant here ATTACK me. And when you attack me, by god, I'm going to respond.
Didn't you just say I was here because ENDV was paying me to be here?
Who or what is a "Tommie?" Are you accusing me of using multiple aliases on this site? Or are you referring to the maker of compression clothing? News flash: the stock price doesn't help or hinder anyone selling ActiPatches and it doesn't help or hinder Whelan -- she can't dilute because the A/S is full so she doesn't care about the stock price.
WTF is with you peanut gallery clowns? Do any of you have even ONE concrete idea or thought?
ENDV is worse than BIEL because ENDV is about to become worthless. They created a new company named SofPulse and now they are going to transfer the assets to that new company, leaving ENDV shareholders holding a great big bag of nothing.
https://www.otcmarkets.com/stock/ENDV/news/Endonovo-Signs-Definitive-Agreement-to-Sell-SofPulse-Brand-Business-and-IP-to-SofPulse-Inc-for-a-minimum-of-50-Million?id=423534
I saw this kind of con game once before at a company called Lifeline (LLBO), but the conman running THAT game wasn't reporting to the SEC so he stayed under the radar.... He transferred all the assets into a subsidiary called Cyrcadia and probably intended to go public with Cyrcadia eventually but his health gave out.
ENDV is reporting to the SEC and if the SEC takes a look at this new asset transfer deal, somebody at ENDV could go to prison. This goes above and beyond mere fines and sanctions, IMO.
I think you can stop worrying about ENDV. That ticker is TOAST.
ENDV is a turd stock. The SofPulse device has less of a market than the ActiPatch because it's so absurdly overpriced.
Anyone who buys either BIEL or ENDV is throwing their money out the window. They are both junk companies and junk stocks.
I never claimed to be subtle.
You didn't answer the question. What would be the motive for paying someone to bash this stock? You seem to think that ENDV shareholders are bashing BIEL, and maybe they are, but who would be PAYING them to do so?
LOL, you and the rest of the peanut gallery here, man.
Here's something to peruse while you eat those peanuts.
https://patentcenter.uspto.gov/applications/10384101
That's the one patent that matters. It expired in July 2021, over two years ago. That means the two-year USPTO window has closed.
No patents, no IP, no assets. Just debt, and financial statements that would embarrass a hot dog stand.
BTW you think anyone here who doesn't shake the pom-poms is PAID to be negative?
Paid bashers on a Pink Limited stock trading at 0.0004?
I almost hate to ask, but... what would be the motive for paying someone to bash this stock?
Whatever.
Talk about the product?
It didn't work for me, but apparently it works for others. Is that merely a placebo effect? I don't know. I wish someone could explain the science behind the concept that PEMF works for some but not for others.
Some clinical trials show that it works while some clinical trials show that it does not work. They are all underpowered studies, IMO.
But the bottom line from an investing standpoint: if it doesn't sell, who cares whether it works or not?
And let's face it: the product absolutely does not sell.
I keep trying to have discussions about this stock and this company, but all I get are bullshit posts like yours that don't even PRETEND to discuss the stock or the company.
But I understand why. If you can't attack the message, attack the messenger.
Hope you feel better now.
Whelan, we know you read these message boards. Tell us why you didn't maintain the patents.
You didn't protect the patents -- the company's MAIN and basically ONLY ASSET. An explanation is due.
The only reason offered by your fan base is that you have a new patent in the hopper that makes the old ones obsolete. I think a company should maintain its existing patents until a new patent takes effect, but maybe you've submitted a patent application for a blockbuster new device. If so, what is the patent application number? Let's take a look.
I think there's a simple explanation: I think you didn't know that the company had to pay maintenance fees on patents. That's the Occam's Razor explanation: Management Incompetence.
Prove me wrong, Whelan. Explain why you let the patents expire. And please don't offer that "we'll tell you when it's appropriate" nonsense. It's appropriate NOW to explain the patent expiration, the delay in the Synergy Deal, the missing financial statements, and Nalepka leaving. Investors have a right to know about ALL of that RIGHT NOW.
The only FACTS that matter:
* BIEL's patents expired because BIEL did not pay the maintenance fees.
* The USPTO offers a 2-year window for reinstating patents if the failure was "unintentional." That window has now closed.
* To reinstate the patents now, BIEL must explain to the USPTO why the failure to pay maintenance fees was "unavoidable."
This discussion is all about the feasibility of some entity (or multiple entities) wanting to buy out BIEL. Without patents, BIEL has very little to attract these entities. They don't have machinery and/or a secret proprietary process to manufacture the device. They don't have buildings or subsidiaries or any other large assets. I keep posing the question "what DO they have to attract a buyer?" and I'm still waiting for an answer.
To reinstate the expired patents, Whelan is going to have to explain why failure to pay the maintenance fees was "unavoidable" and not simply "unintentional," and why it was unavoidable to file the "unintentional" petition for the two years following expiration.
Why didn't Whelan reinstate the patents? The only excuse I'm reading here is that BIEL has new designs and new patents that make the old patents unnecessary. My response to THAT is: What is the patent application number of this new patent? Let's read it. Is it a Design patent or a Utility patent?
* If it's a Design patent, those piggy-back off the original patent (US-7551957-B2) and adopt the original patent's termination date. If the original patent is expired, that's useless.
* If it's a Utility patent, that's going to require new clinical studies and a new FDA application.
It's simple: new Utility patent, new FDA clearance. Both of those things take time and money.
BTW I'm tired of hearing how everyone who doesn't shake the pom-poms here has an "agenda" to destroy this company. That's nonsense (except in the case of diddlysquat and who knows or cares what HIS problem is). It comes down to this: if someone is going to pump a buyout here, they are going to have to defend their pump.
Not that it matters. Nobody is reading this board except investors who have already made up their minds about this stock -- opinions and sentiments are NOT being changed here.
We have to GUESS what you are trying to say and what you "know or don't know" because you are vague and ambiguous.
I know you think you are a wordsmith, but I'm afraid you are not. You are just a word spewer, sorry to say.
If you want to make some concrete clear statements about how you think patent lawyers, lobbyists, and money can solve Whelan's patent problems, then by all means, have at it. I won't hold my breath though.
I made money doing patent searches when I was in college, but I'm not a patent lawyer. However, the USPTO's documentation, if you bothered to read it, is clear: Whelan needs to submit an explanation why the non-payment of maintenance fees was "unavoidable." That is the USPTO's word, not mine, and that is the ONLY way the patents can be reinstated.
It's simple, it's clear, and while patent lawyers might be able to advise Whelan how to word it, they don't know why, so they can't write it. So yes, only Whelan can fix it.
And are you forgetting how you said that lobbyists and influencers and money can fix this patent problem? I'd like to.
You don't understand why the patents terminated, do you?
And you don't understand what the USPTO wants Whelan to do in order to reinstate them, do you?
That's the problem with this discussion, isn't it? You don't have any idea what the problem is, and you don't understand the only path Whelan has to fix it. But that's not stopping YOU, no sir, it's full steam ahead on the buyout pump, and anyone who tries to point out the faqcts or the truth gets mocked and ridiculed.
I hope that makes you feel good because it's not going to make you money.
What it IS: a typical zombie biotech.
With bagholders.
And with 25 billion O/S, it has more than the usual number of bagholders.
Nothing more complicated than that.
We've all been bagholders. Me, personally, when I make a bad guess, I've learned to accept my losses and move on.
But THIS group just insists on hanging on and pushing my buttons. Fine, I have time to torment those who persecute me. I'm going back to school in January though, at which time I will have no more time to suffer these fools.
Here's the scoop: the patents are expired.
Your rhetoric about multiple buyers getting into a bidding war for BIEL and fixing all that is wrong with BIEL with lobbyists and lawyers and buckets of money is simply bullshit. Nobody wants to buy BIEL. Anyone can buy the product from China with their own branding and sell it themselves.
That's the scoop.
It boggles the mind. This CEO's main job was to protect the assets. The company had only one real asset -- the patents. They don't have manufacturing equipment or buildings or an established client base.
The patents were IT. Now they basically have nothing to attract a buyer.
LOL, what kind of twisted logic is that?
You're saying that if Whelan approached a patent lawyer about patents that expired 30 months ago due to nonpayment of maintenance fees, that patent lawyer would take the job and take Whelan's money, even though that patent lawyer knew they couldn't get the patents reinstated?
Because if that patent lawyer was ethical and didn't take Whelan's money, that Patent Law Firm would go out of business?
I think you watch too much TV.
I'm responding to their insults.
And I don't think they are "lucky" for believing because I don't think they believe. I think they PRETEND to believe.
At some point, every pennystock gambler learns that sometimes you have to take a loss, take your medicine, and move on. These BELievers haven't reached that point yet. Maybe they never will. Boo hoo.
let's look at the numbers.
Whelan let the patents expire in 2021.
R&D total expenses in 2021: $251,490
R&D total expenses in 2022: $253,809
R&D in Q1 2023: $66,942
Other General and Administrative Expenses (where they book salaries) 2021: $327,532
Other General and Administrative Expenses 2022: $288,712
Other General and Administrative Expenses Q1 2023: $37,186
Look at those numbers.
Now say with a straight face that you believe this company let their patents -- their intellectual property and only assets -- expire in 2021 because they have new designs and new patents on the way.
"Other Expenses" for Q1 2023, including salaries and compensation and other expenses not booked elsewhere, was $37,186. For an entire quarter. That would be low if they had only one paid employee. Yet you believe they have a TEAM of paid employees, some of whom are designing and testing new products and corresponding patents and doing regulatory work.
Remember -- straight face.
.
LOL, you apparently think you DO have a clue. Act on that clue and SLAP THAT ASK.
Just curious: do you think that BIEL has improved products and new patents on the way? I mean honestly, truthfully, is that what you think?
And do you think a new patent (translated: new design) would not require new FDA clearance?
Do you understand that unless the design is DRASTICALLY DIFFERENT, any design change patents would piggyback on the first patent and expire at the same time as the original patent? That is patent law. And since that original patent is terminated.... there is no point in filing any more patent applications until they reinstate that original patent.
I love this bullshit about new designs and new patents. The most recent financial statement proves that they are spending as little as possible on R&D and salaries. They are operating on a shoestring budget. they couldn't even pay the maintenance fees on the existing patents but you think that somehow, secretly and off the books, they are spending $$$$ on new designs, new patents, new regulatory approvals..... Riiiiiiight.
But I must be wrong! Common sense, logic, and reasoning have no place in the magical world of BIEL! Slap that Ask! What a bargain at this price! The only remaining decisions are what color to choose for the Lamborghini and what to name the yacht!
You need to read the USPTO website before saying anything further on the subject..
Patent lawyers can't help. It's not a legal question.
Good luck with that, Paul. Knock yourself out.
I understood it just fine the first time. You think that a buyer could throw money and influence and political pressure at the patent problem and convince the USPTO to reinstate those patents against their published guidelines. I do not think that is true.
That happens on TV shows like Billions but Bobby Axelrod is a fictional character and not every politician and political figure is corrupt. Sorry.
You want to throw your money at BIEL hoping for a buyout, fine, you do that, and I wish you luck. I don't like the odds, myself, but that just leaves more for you.
in your opnion, or maybe in your wishful thinking.
People have different risk tolerances. You choose to throw your money at that, I do not, let's accept the difference.
Money and lobbying won't fix the patent issue. The only remedy is Whelan explaining to the USPTO that the non-payment of maintenance fees was "unavoidable." That's the USPTO's word, not mine.
She had a brief window in 2021 when she could have reinstated the patents without that explanation, but that window closed. Now she has to offer an explanation to the USPTO and they have to "accept the explanation" (again, the USPTO's words, not mine).
What could her explanation be? "Unavoidable?" The patents expired in 2021 when BIEL was releasing PR's and shareholder newsletters boasting about 400% increases in revenues. It's going to be difficult for Whelan to use MONEY as an excuse.
Her internet went down? She fell into a coma? She was kidnapped?
I don't know how stringent the USPTO is about these matters. I've never seen a company let patents expire for non-payment of maintenance fees before. It boggles the mind. Who would let patents expire for something so trivial and inexpensive? But then who would forget to renew a CE Mark and let their Corporation status terminate in their state of incorporation?
Am I naive in my belief that the USPTO can't be bribed? No, not naive -- realistic. Yes, anything can happen, but I wouldn't invest MY money on the hopes that a government official can be bribed.
There's nothing new from Gramps.
Somebody re-posted a 2018 Gramps video from Youtube.
Yes but were talking about monies paid by SMI to GTHP that were then owed to Shenghuo.
But again, I don't care about China or your claims against Faupel and Blumberg. I only care about the clinical trials being completed, the FDA submission, and FDA approval. I believe the FDA will approve the application THIS TIME.
IF GTHP gets any money from SMI, that would be icing on the cake. I don't think SMI has that kind of money. But IF the doctors who ran that study publish their results, that is a huge win for GTHP because they could then submit that study with their US study.
I don't have a beef with GTHP over any of the Chinese agreements. I learned long ago not to invest in China Hype. I did not buy this stock because of anything that might or might not happen in China.
Or Turkey or Africa or anywhere but the USA.
You're asking me why GTHP signed an agreement with Shenghuo? I ask you, why not, in absence of a better Chinese representative?
All I'm saying is that maybe you have a beef with Faupel and Blumberg but GTHP is not a defendant so GTHP doesn't get harmed or helped by the outcome of that case.
Just curious, Paul: How much are you asking in damages?
The disputed loan is $64,000. How much more $$$ might Faupel and Blumberg be forced to pay if they lose all the remaining claims?
AND.... Erin Sanders removed "Willing to Locate" from her tagline on LinkedIn.
It's still in her profile.
If the Whelans spent more time trying to run this company and less time reading about themselves on message boards, maybe their financial situation would improve.
GTHP is not a defendant in that case.
That attorney didn't file a complaint against GTHP.
That was not a press release.
And a CEO that meets shareholder complaints with aggression reveals a person who should not be CEO of a publicly traded company.
"Regardless of what we accomplish?" What, exactly, has Whelan accomplished in the last 18 months?
Shareholders aren't critical of Whelan's "accomplishments," whatever they are. Investors are critical of the failure to sell product, the failure to protect the patents, the failure to release PR's, and the failure to file financial statements.
BTW, Investors Hangout is a joke. At least the main joker, wbeacham, has left -- that guy's passive-aggressive breathless prose was torture to read.
Synergy was never revealed to be ANYTHING.
Apparently, the company had a distribution agreement with a guy in Kathmandu, but like many distribution agreements in this business, it never came to anything. The Kathmandu guy kind of vanished into thin air.
Privately, most notably in a Zoom shareholder meeting, BIEL's CEO and Sales VP hinted that it was more than just a distribution agreement, but they never publicly said anything about Synergy and never mentioned Synergy in a single filing. That means there IS no Synergy Deal. It's not fake and it's not real. It's just a distribution agreement that didn't pan out. Anything else was just a rumor created and fostered by unethical people.
OTCmarkets got rid of the STOP sign and replaced it with double black diamonds and the label "Expert Market."
Most brokers won't let the investor buy "Expert Market" stocks. Some Canadian brokers allow it, but I'm pretty sure there are zero US brokers that will allow you to buy an Expert Market stock. US brokers allow investors to SELL "Expert Market" tickers, but not BUY them.
For that reason, I strongly believe that Whelan will file that annual report. Allowing this thing to go to Expert Market would cause even the most diehard supporters to revolt.
Maybe one thing: Erin Sanders appears to be looking for a new job, based on her LinkedIn page.
Otherwise, you missed nothing.
The next "event" will be March 31st when CEO Whelan has to decide whether to disclose some information or go to Expert Market. I don't think OTCmarkets will give her a grace period -- they changed the status to Pink Limited on the morning after Q2 financials were due.
I acknowledge that what I believe to be the facts are only what is contained in GTHP's filings with the SEC.
I am really only trying to participate in a discussion, and I appreciate your participation. It's an academic duscussion for me because I don't think SMI is going to pay Guided 2.2 million. Frankly, I'm only here for the FDA play in the USA -- I don't have much faith in the "China Play" of SMI. They might actually submit an application to the NMPA (fka CFDA), but I'd be very surprised if SMI has $2.2 million USD. They look like a small entity that does little more than manufacture glass blood collection tubes.
I do think the Chinese study will help Guided get US FDA approval. Can't hurt.
I will try to follow the Conte trial in March. You should keep us posted. Thanks!